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Abstract 
There is growing evidence that putative gene regulatory networks including cardio-enriched 
transcription factors, such as PITX2, TBX5, ZFHX3, and SHOX2, and their effector/target genes along 
with downstream non-coding RNAs can play a potentially important role in the process of adaptive 
and maladaptive atrial rhythm remodeling. In turn, expression of atrial fibrillation-associated 
transcription factors is under the control of upstream regulatory non-coding RNAs. This review 
broadly explores gene regulatory mechanisms associated with susceptibility to atrial fibrillation—
with key examples from both animal models and patients—within the context of both cardiac 
transcription factors and non-coding RNAs. These two systems appear to have multiple levels of 
cross-regulation and act coordinately to achieve effective control of atrial rhythm effector gene 
expression. Perturbations of a dynamic expression balance between transcription factors and 
corresponding non-coding RNAs can provoke the development or promote the progression of atrial 
fibrillation. We also outline deficiencies in current models and discuss ongoing studies to clarify 
remaining mechanistic questions. An understanding of the function of transcription factors and non-
coding RNAs in gene regulatory networks associated with atrial fibrillation risk will enable the 
development of innovative therapeutic strategies. 
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Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia in current clinical 
practice. There are different predisposing risk factors and conditions for the development of 
AF, but patients diagnosed with asymptomatic non-familiar AF do not have any traditional 
risk factors. Proarrhythmogenic molecular remodeling, broadly defined as any change in 
atrial gene regulation that promotes atrial conduction disturbances, is potentially crucial for 
unraveling a sudden-onset of AF [1]. 
 
There is growing evidence that putative gene regulatory networks (GRNs) including 
cardio-enriched transcription factors (TFs) and their target genes can play a potentially 
important role in the process of adaptive and maladaptive atrial rhythm remodeling [2]. In 
addition, human genome-wide association studies (GWAS) have successfully identified 
chromosome loci of DNA variants associated with increasing risk for AF and their closest 
genes including those coding for cardio-enriched TFs (reviewed in [3, 4, 5, 6]). Recently, a 
number of studies have demonstrated that cardiac GRNs are under the control of 
interleaved networks of regulatory non-coding RNAs (ncRNAs), which include 
microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Mature miR transcripts 
(approximately 22-nucleotide long) act as inhibitors of target gene expression by either 
promoting mRNA degradation or suppressing translation. In this context, lncRNAs (more 
than 200 nucleotides long) can either activate or suppress gene expression by regulating 
chromatin conformation and TF binding or through sequestering miRNAs from their target 
mRNAs. Contemporary research has revealed that ncRNAs are dysregulated in many forms 
of adult heart disease in both patients and animal models [7, 8]. In particular, it was 
evidenced that ncRNAs may form additional critical layers of the intricate modulator 
architecture for the control of atrial gene expression [9, 10, 11, 12, 13, 14, 15]. 
 
This review broadly explores the gene regulatory mechanisms associated with 
susceptibility to AF providing key examples within the context of both cardiac TFs and 
ncRNAs. These two systems appear to have multiple levels of cross-regulation and act 
coordinately to achieve effective control of atrial rhythm effector gene expression. 
Perturbations of expression balance between TFs and ncRNA networks can promote AF 
development. In this context, several lines of evidence indicate that the TF-miRNA 
blueprint for AF susceptibility is distinct from that associated with chronic AF [16, 17]. 
Accordingly, the aim of the present review is to summarize the current evidence on the role 
of the cardiac TF-ncRNA co-regulatory networks in predisposition to AF. Deciphering the 
interplay between cardiac TFs and ncRNAs will likely lead to a more translational approach 
for preventing and treating AF. 
Sources of atrial ectopic beats triggering fibrillation 
Spontaneous self-terminating episodes of AF are one of the most common heart rhythm 
disorders. Ectopic pacemaking activity (i.e., electrical impulse generation outside the sino-
atrial node (SAN)) and re-entry of excitation wavefronts are considered the most probable 
mechanisms involved in AF development. There is a substantial body of research 
demonstrating that erratic atrial premature beats can trigger AF in the presence of a 
vulnerable substrate. Once initiated, AF itself can lead to the so-called electric remodeling 
of atrial myocardium, which promotes fibrillation maintenance [1]. 
 
Focal triggering sites of spontaneous AF can reside in various anatomical structures 
such as the left atrial (LA) appendage as well as LA myocardial muscle extensions 
(“sleeves”) located in the pulmonary veins (PVs) (Fig. 1). The PVs are characterized by a 
unique myofiber architecture and electric properties that can lead to the ectopic activity that 
triggers AF, and PV ablation is widely used to terminate AF [18].  
 
 
 
Fig. 1. Atrial activation patterns and transcription factors involved in the development of atrial fibrillation. a 
Normal atrial activation during sinus rhythm (SR). The sinus node (SAN) located at the entrance of the right 
superior cava vein in the right atrium (RA) generates electrical impulses which are distributed within large areas 
(big wide arrows) of the RA and left atrium (LA) to create normal rhythm. RV and LV right and left ventricles. b 
Atrial ectopic (non-SAN) rhythm activation. Ectopic pacemaking activity (semi-circular arrows) in the LA, 
pulmonary veins (PVs), or RA can trigger the development of atrial fibrillation (AF). Clinical studies have 
evidenced that more than 80% of the AF trigger impulses originate within PV muscular sleeves and LA muscles. 
NKX2.5, SRF, MEF2C, GATA-6, PITX2, TBX5, ZFHX3, and SHOX2 are the core cardiac TFs, which are 
thought to be responsible for initiation of AF. TFs implicated in susceptibility to AF by genetic and functional 
assays in animal models coupled with studies of samples from AF patients are marked in red, while those marked 
in gray have only sporadically been associated with an increased risk of AF. (Heart images taken from 
http://www.michiganmedicalreport.com/michigan_cardiology/details/241 
/podcast.aspx, modified) 
  
Some clinical data suggest that the right atrium (RA) could also play a role in AF 
triggering [19]. However, the LA and RA have different susceptibilities toward developing 
arrhythmias: LA arrhythmias are more frequently observed [20]. Atrial mapping in patients 
shows that paroxysmal AF may originate in the RA in no more than 20–25% of cases [21, 
22]. 
 
In adult mice as well as in humans, the LA and RA differ in their gene expression 
patterns [23, 24, 25]. In this sense, some cardio-enriched TFs and miRNAs [26, 27] 
involved in the development and progression of AF demonstrating left-right asymmetry in 
their expression in atrial myocardium. Within the scope of this review, the expression 
patterns of several of such TFs and miRNAs in the human left and right atria are 
schematically outlined in Fig. 2. 
 
 
 
Fig. 2. Schematic representation of transcription factors and microRNAs expression signatures in human left and 
right atria. The color intensity is proportional to relative differences in expression levels of the gene in the RA vs 
LA; lightly gray denotes a relatively low while black denotes a relatively high expression. RA right atrium, LA left 
atrium. Respective references are shown in brackets 
In addition to interatrial ectopic pacemaking activities, pathophysiological cardiac 
conditions, such as heart failure, valvular heart disease, hypertrophic cardiomyopathy, acute 
myocardial infarction, and congenital heart disease, can lead to AF development. 
Intriguingly, it was recently found that accumulation of atrial adipose tissue is associated 
with AF [28]. Moreover, it was evidenced that human adult atrial epicardial cells 
differentiate into adipocytes [29] that, in turn, can contribute, under certain conditions [30], 
to the formation of AF substrate. 
  
Transcription factors–microRNA co-regulation in atrial fibrillation 
AF susceptibility is associated with rapid transcriptional remodeling of atrial 
myocardium. It is generally accepted that TFs and miRNAs jointly regulate target gene 
expression by either feed-forward or feedback mechanisms. However, the different roles of 
many TFs and miRNAs in the development of AF have been separately studied. In spite of 
such a mechanistic dissociation in the field of basic AF research, we will try to bring 
together the scattered findings on the atrial TF–miRNA circuits underlining AF 
susceptibility. The analysis of opposite correlations between TF and miRNA expression 
levels have allowed the identification of TF–miRNA regulatory circuits which are of 
particular interest in the context of atrial predisposition to AF development. 
PITX2/miRNA circuits 
PITX2 (pituitary homeobox 2 or paired-like homeodomain transcription factor 2), a 
member of the bicoid class of homeobox genes, is located within the human 4q25 AF-
associated locus. In humans, the gene is transcribed into four distinct variants: PITX2A, 
PITX2B, PITX2C, and PITX2D. PITX2C, the predominant cardiac variant of the gene, is 
more highly expressed in the adult LA compared to RA [31, 32, 33]. PITX2 has been 
extensively studied, particularly its functions in heart development. It is widely recognized 
that PITX2C implicated in multiple pathways of cardiac left–right (L–R) asymmetry [34, 
35] also regulates L–R atrial identity. The phenotype of PITX2C-deficient mice is 
characterized by RA isomerism with two SANs at both right and left regions of sinoatrial 
junction, each expressing the same panel of SAN-specific molecular markers [36]. Of note, 
pediatric patients with RA isomerism, usually with two SANs, are characterized by a high 
incidence of AF [37]. There is growing evidence suggesting that PITX2 plays a role in 
regulating gene expression as well as electrical, functional, and structural integrity in adult 
LA [38]. Of note, PITX2 and NKX2-5 control the development of LA myocardial “sleeves” 
in the PVs (see Fig. 1), the most frequent arrhythmogenic focus in patients with AF [39]. 
 
GWAS in humans revealed that genetic variants at chromosome 4q25 constitute the 
strongest locus associated with AF. Some of these 4q25 variants are located in the 
proximity of the PITX2 gene suggesting that modulations of PITX2 expression in atria are 
associated with susceptibility to AF development [40]. In this sense, CRISPR-Cas9-
mediated editing of one of the AF-associated 4q25 variants proximal to PITX2 in human 
stem cell-derived cardiomyocytes significantly downregulates PITX2C expression. This 
downregulation is most likely due to alteration of the TFAP2a (transcription factor AP-2 
alpha) binding site(s) at the risk variant region that leads to inactivation of a putative PITX2 
enhancer [41]. 
 
Loss-of-function mutations in PITX2 have been shown to be associated with familiar 
AF [42]. In addition, functional studies show that the mutation in the 5′ untranslated region 
of the PITX2 gene, identified in probands with severe AF, leads to downregulation of this 
gene expression in atrial myocytes at both basal conditions and rapid pacing [43]. Data 
from animal models are well in line with these findings. In mice, PITX2 haploinsufficiency 
predisposes to pacing-induced AF indicating that reduced PITX2 levels promote an 
arrhythmogenic substrate as observed in different mouse models [31, 44, 45, 46]. In 
addition, unstressed adult PITX2 mutant mice manifest electrocardiographic signs of sinus 
node dysfunction (SND) which is frequently associated with AF development in humans 
[47]. In this regard, it should be noted that the abnormal electrophysiological substrate for 
SND is localized in the RA while the majority of triggers and substrates for AF originate in 
the LA (see Fig. 1). Similarly to what has been observed in mice, there is an association 
between LA PITX2 downregulation and increased atrial arrhythmogenicity in a rat 
experimental model of hypertension with spontaneous atrial arrhythmias [48]. In model 
cell-based assays, PITX2 knockdown significantly decreases the expression level of the 
ZFHX3 TF which, in turn, may contribute to the occurrence of AF [49].While experimental 
data from animal models of PITX2 knockdown do provide evidence that PITX2 deficiency 
can play a role in susceptibility to AF, the results of transcriptomic profiling of atrial 
myocardium from patients with AF are not yet conclusive. Particularly, increased [50], 
decreased [45, 51], or unaltered [33] PITX2C levels were detected in atrial biopsy 
specimens from AF patients. PITX2 modulates atrial resting membrane potential and alters 
the effectiveness of Na channel blockers; antiarrhythmic agents were found to be more 
effective in suppressing arrhythmias in atria with reduced PITX2C mRNA levels [52]. In 
humans, AF risk single-nucleotide polymorphisms (SNPs) are associated with increased 
PITX2 expression [53]. These findings, taken together with the above data, indicate that the 
direct correlation between PITX2 expression levels in the atrial myocardium and a 
multifactorial disorder like human AF remains elusive. (For more details, see the comment 
[54].) 
 
PITX2 can contribute to regulation of atrial contractility and arrhythmogenesis through 
multiple pathways including a variety of ion channel, calcium handling, and gap junction 
proteins that are crucial for atrial pacemaker activity [38]. In addition, the analysis of 
cardiac expression of multiple miRNAs regulated by PITX2 in the heart has yielded some 
interesting results in relation to the mechanisms by which PITX2 may modulate several 
pathways leading to AF [2, 38]. PITX2 expression is co-localized with the expression of 
miR-17-92 and miR-106b-25 clusters and loss of PITX2 causes decreased expression of the 
corresponding miRNAs. Mice deficient in these miRNA clusters reveal characteristics 
similar to those of PITX2 mutant mice, including a high predisposition to induced AF and 
dysregulation of SHOX2 and TBX3 expression [55]. 
 
Interestingly, when miRNA expression levels were found to either increase or decline 
during AF development [12, 56], they were likewise found to be modulated by PITX2 as 
revealed in two distinct PITX2 loss-of-function murine models that recapitulate some 
aspects of the human AF. Remarkably, expression of miR-21, which negatively regulates 
PITX2 in atrial-derived cells [17], was downregulated in these mutant mice [46]. Of note, 
expression of miR-21 is upregulated in the LA of patients with long-term persistent AF as 
well as in a mouse model of spontaneous AF [12, 57, 58] and after short-term AF episodes 
in pigs; transfection of atrial cardiomyocytes with miR-21 mimic leads to PITX2 
downregulation [17]. In human patients, plasma levels of miR-21 significantly increased 
after AF ablation [59]. Together, these results highlight a possible reciprocal regulation 
between PITX2 and miR-21 in various AF settings, although the actual mechanism by 
which they might form feed-forward/feedback loops to propagate their adverse effects on 
atrial myocardium is not well understood. 
 
PITX2C was shown to negatively regulate the expression of miR-1 in the adult mouse 
LA [45]. When overexpressed in normal or infarcted rat hearts, miR-1 represses the 
expression of potassium channel subunits and connexins and thus provokes 
arrhythmogenesis [60]. In the porcine model of spontaneous self-terminating AF, induced 
ectopic tachyarrhythmia caused rapid downregulation of PITX2C which was inversely 
correlated with miR-1 upregulation in the LA of paced animals [17]. In contrast, expression 
of miR-1 is downregulated in patients with chronic persistent AF [61]. Several lines of 
experimental evidence suggest that PITX2 also negatively regulates miR-29a expression in 
atrial myocardium [46, 62]. Importantly, a significant increase in the expression levels of 
miR-29a was observed in both LA [57] and RA [63] appendages from patients with chronic 
AF compared to those from the sinus rhythm controls. The calcium voltage-gated channel 
subunit alpha1C (CACNA1C) gene, playing an essential role in cardiac arrhythmogenesis, 
was identified as a target gene of miR-29a in atrial myocytes [63]. In this sense, it seems 
reasonable to suggest that suppression of aberrant activity of miR-29a by PITX2 could 
ameliorate AF.  
As in the case of miRNAs, lncRNAs could also be potent regulators of AF risk factors 
[64]. Recently, RNA sequencing of human LA/RA pairs identified an intergenic lncRNA 
named PITX2 adjacent noncoding RNA (PANCR). Expression of PANCR positively 
correlates with PITX2C levels in human LA biopsy samples and PANCR may act as a 
positive regulator of PITX2C: PANCR knockdown represses PITX2C expression and in this 
regard mimics the consequences of PITX2C inactivation on mRNA and miRNA expression 
in differentiated cardiomyocytes [65]. 
 
Together, the data illustrate multiple levels of PITX2 regulation, potentially requiring 
further investigations of any proposed causative association between PITX2 expression 
levels in the human adult atria and the first clinically observable manifestations of a 
transient irregularity of the atrial rhythm. 
TBX5/miRNA circuits 
TBX5, a member of the Brachyury T-box TF family, is widely expressed in the human 
heart, including the atria [66]. TBX5 undergoes extensive alternative splicing, generating 
several transcript variants encoding protein isoforms with different properties [67, 68]. 
Alteration of TBX5 levels affects the expression of hundreds of genes, including genes 
implicated in AF pathogenesis [69, 70, 71]. 
 
The involvement of TBX5 in human AF development was suggested through the 
analysis of the TBX5 gain-of-function mutation in a large family of patients with mild Holt–
Oram syndrome (HOS) and paroxysmal AF [72, 73]. However, TBX5 loss-of-function 
mutations were found to be associated with a predisposition to the onset of AF in a subset 
of HOS patients [74]. Moreover, the TBX5 loss-of-function mutation which decreases TBX5 
transcriptional activity was detected in patients with “lone” AF [75], suggesting that TBX5 
haploinsufficiency could contribute to AF development. In this regard, it was recently 
found that TBX5-knockout human cardiomyocytes are characterized by marked pro-
arrhythmic activity [71]. 
 
The results of a number of GWAS analyses have linked intronic sequence variants of 
theTBX5 gene to PR interval prolongation which is a surrogate AF risk marker in patients 
[76]. This is in line with growing evidence showing a strong association between several 
SNPs in the TBX5 gene and lone AF in patients [68, 77]. Recent cis-expression quantitative 
trait locus analysis suggests that altered TBX5 expression in the human LA plays a role in 
AF susceptibility [6]. 
 
Additional evidence linking TBX5 and AF has emerged from studies in murine models. 
In mice, adult-specific TBX5 deletion causes the rapid onset of AF affecting the expression 
of calcium-handling and other AF-susceptibility genes in atrial cardiomyocytes. In addition, 
it was found that TBX5 directly activates PITX2, while TBX5 and PITX2 antagonistically 
regulate membrane effector genes. Most importantly, it has been demonstrated that PITX2 
suppression reverses the pro-arrhythmic effects of TBX5 knockdown suggesting that 
deficiency of both, TBX5 and PITX2 could lead to the onset of AF, but through opposite 
mechanisms [78]. Interestingly, PITX2 itself regulates the expression of TBX5 in 
cardiomyocytes [79], and PITX2 insufficiency leads to molecular and electrophysiological 
impairment of calcium homeostasis in the mouse LA mediated by Wnt signaling genes and 
miRNAs [46]. 
  
Some studies have shown that miRNAs can act as essential components in TBX5-
signaling networks at AF, through either regulation of their expression by TBX5 or 
regulation of TBX5 itself. In mouse cardiac cells and zebrafish embryos, TBX5 was found to 
be able to regulate the expression of several miRNAs [80] and, in particular, miR-19 [81, 
82]. MiR-19 expression levels are significantly increased in the LA of patients with 
paroxysmal AF [83]. In the mouse heart, miR-19 is transcribed as part of the miR-17-92 
cluster which expression is positively regulated by PITX2. TBX5 is a target gene of both 
miR-10a and miR-10b [84]. Expression of miR-10b was found to be upregulated in LA 
biopsies from patients with chronic AF and valvular heart disease [27] and miR-10b plasma 
levels are decreased in AF patients after catheter ablation [85]. In the porcine model, short-
lasting atrial tachyarrhythmia was associated with significant upregulation of both miR-10a 
and miR-10b coupled with decreased TBX5 expression in the LA of paced animals that may 
be permissive for AF development [17]. TBX5-dependent enhancer lncRNAs might also be 
functionally involved in TBX5 regulated gene expression in atrial myocytes. Particularly, it 
was found that RYR2-associated cis-element RNA (RACER), a TBX5-dependent lncRNA, 
is required for expression of ryanodine receptor 2 (RYR2), the major calcium release 
channel on the sarcoplasmic reticulum in cardiomyocytes. As a whole, more than two 
thousand TBX5-dependent ncRNAs were identified in the mouse atria by deep sequencing 
[86]. 
 
Together, all these data indicate that alterations in TBX5 expression levels in atrial 
myocardium may be a trigger for the production of the arrhythmogenic substrate. 
ZFHX3/miRNA circuits 
ZFHX3, the zinc finger homeobox 3 gene (formerly known as ATFB1), encodes a TF 
which was described as a transcriptional repressor for myogenic differentiation [87]. 
ZFHX3 is highly expressed in the adult mouse heart [88] and human stem cell-derived 
cardiomyoblasts [89]. ZFHX3 regulates transcription via direct interaction with predicted 
AT (adenine- and thymine-rich) motifs in the promoter region of target genes. 
 
ZFHX3 located on the human chromosome 16q22 is one of the major AF susceptibility-
conferring genes found by SNP scanning in Caucasian [90], European [91], Chinese [92], 
and Japanese [93] populations. Recently, gene-based association tests in AF patients linked 
single common genetic polymorphisms of the ZFHX3 gene with different AF clinical 
phenotypes (paroxysmal and persistent AF), LA remodeling and, in turn, with AF 
recurrence after ablation [94, 95]. 
 
The results coming from in vitro cell-based assays show that ZFHX3 can play an 
important role in AF predisposition and also support GWAS data on ZFHX3 involvement 
in the genesis of human AF. It was found that tachypacing leads to ZFHX3 downregulation 
in cultured atrial HL-1 myocytes. In turn, ZFHX3 knockdown in HL-1 myocytes 
contributes to upregulation of mediators of inflammatory signaling [96] and deregulation of 
calcium homeostasis underlying increased atrial arrhythmogenesis [49]. 
 
There is growing evidence that ZFHX3 molecular interactions with other AF-
susceptibility genes, such as PITX2 and TBX5, can markedly increase AF risk. In particular, 
experiments with both heart-irrelevant cell lines [97] as well as HL-1 atria-derived cells 
[46] revealed that silencing of ZFHX3 expression significantly downregulates the 
expression of PITX2C. Conversely, overexpression of ZFHX3 increased PITX2C 
expression. Remarkably, ZFHX3 knockdown also significantly increased expression of 
TBX5 [97]. 
  
ZFHX3 was predicted to be a downstream target gene of miR-1 and contains two miR-1 
binding sites at its 3′-untranslated region; cell transfections with miR-1 mimics significantly 
decreased expression of ZFHX3 at both mRNA and protein levels [97]. Reduced levels of 
miR-1 expression were found in human AF [61] suggesting this could lead to a certain 
degree of ZFHX3 and PITX2 upregulation in diseased atria, preventing, to some extent, 
further aggravation of AF. 
SHOX2/miRNA circuits 
SHOX2, the short stature homeobox 2 gene, encodes a TF which controls the 
development and function of SAN (the primary site for initiation and maintaining of the 
normal sinus rhythm) located in the adult RA (Fig. 1). The human SHOX2 encodes two 
alternatively spliced transcripts. In a cardiac developmental context, SHOX2 functions as a 
pro-pacemaker factor and antagonizes the NKX2-5 activity in the PV myocardium (see Fig. 
1) that is well known for its arrhythmogenic capacities [98, 99]. Transcriptome analysis did 
not reveal any significant differences in SHOX2 expression levels between the LA and RA 
in sinus rhythm patients (see Fig. 2 and references therein). 
 
Expression analysis revealed significantly reduced SHOX2 transcript levels in RA 
samples from patients with early-onset AF. In addition, the miR-92b-5p was identified as a 
putative negative regulator of SHOX2 expression in particular cohort of AF patients 
carrying a mutation in the 3′ untranslated region of the SHOX2 gene [100]. However, the 
authors of this work investigated RA tissue, while AF normally originates in the LA. In 
mouse models, it was shown that PITX2 which is highly expressed in the LA and PV 
myocardium negatively regulates SHOX2 directly [44] or indirectly through upregulation of 
the miR-17-92/106b-25 cluster, that in turn represses SHOX2. Additionally, it was found 
that SHOX2 upregulation in the fetal LA promotes LA ectopic automaticity [55]. It is 
therefore tempting to speculate that an imbalance between the expression dosages of PITX2 
and SHOX2 in the LA and PV myocardium may lead to AF. In this context, it is likely that 
inhibitors of excessive expression of SHOX2 in the LA could help prevent AF 
development. 
Concluding remarks 
Results of human AF GWAS screenings coupled with data from conditional gene 
manipulations in mice and cell-based functional assays identify a set of TF-miRNA co-
regulatory loops as putative disease modules orchestrating susceptibility to induced or 
spontaneous AF. These modules include PITX2, TBX5, ZFHX3, and SHOX2 TFs and their 
upstream and downstream miRNAs (Fig. 3). Previously, these TFs have either been 
implicated in cardiac development and differentiation or have been shown to be mutated in 
patients with different subtypes of AF. Notably, the association between these TFs is 
significant, implying not only a synergetic, but also a previously unrecognized opposite 
regulation of the expression of common downstream AF-associated genes [78]. 
Remarkably, there is a growing evidence suggesting that other cardiac TFs, such as NKX2-
5, SRF, and GATA-6, may be associated with or responsible for early-onset human AF [16, 
101, 102, 103]. 
  
 
 
 
Fig. 3. Cardiac transcription factors and related microRNAs that are known or suggested to be involved in the 
initiation of AF. AF susceptibility, as functionally validated using in vitro and in vivo models, is associated with 
deregulated expression of transcription factors (PITX2, TBX5, ZFHX3, and SHOX2) and related miRNAs (miR-
21, miR-19, miR-17-92, and miR-92b). Bold arrows (black/white) denote either up or down expression of the 
genes. The question mark represents a speculative assertion that SHOX2 upregulation in the LA or PV 
myocardium might promote ectopic automaticity. Whether miR-10a and miR-10b are directly involved in AF 
predisposition remains to be experimentally determined. Of note, the miR-17–92 miRNA cluster generates a single 
polycistronic primary transcript that yields six mature miRNAs: miR-17, miR-18a, miR-19a, miR-19b, miR-20a, 
and miR-92a [107]. LA left atrium, PVs pulmonary veins 
Could studies of atrial-associated TF-miRNA modules identify novel therapeutic targets 
and help to develop novel treatment strategies for the primary prevention of AF 
development or AF recurrence? Within each described module, a dynamic expression 
balance between TFs and miRNAs may have a certain clinical relevance as it was found 
that a low activity of PITX2, TBX5, and, probably, ZFHX3 can lead to or be associated with 
irregular ectopic atrial activity. In the porcine model of transitory AF, short-term atrial 
pacing resulted in significant upregulation of miR-21 and miR-10a/b which was associated 
with the downregulation of their respective target TFs, PITX2, and TBX5 [17]. In this 
respect, antagomiR-induced knockdown of miR-21 and miR-10a/b might be a means to 
prevent recurrence of AF paroxysms. However, future studies directed at an in-depth 
understanding of the pathways regulated by atrial TF-miRNA circuits in various AF 
settings are necessary before translational treatment strategies can be considered. 
 
Besides the role as putative therapeutic targets, the cardiac-enriched nc-RNAs discussed 
in the present review may be employed as prognostic and diagnostic biomarkers in AF. 
Indeed, it is increasingly recognized that circulating plasma miRNAs could be promising 
biomarkers for risk stratification in AF patients [12, 104]. In particular, plasma levels of 
two PITX2-associated miR partners, miR-1 and miR-21, are decreased in patients with 
sustained atrial tachycardia [105] and paroxysmal AF [59, 106], respectively. In contrast to 
miRNAs, the profiling of circulating lncRNAs is only starting to emerge as a putative 
biomarker tool for heart disease.  
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